Galera Therapeutics Files 8-K
Ticker: GRTX · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1563577
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Galera Therapeutics filed an 8-K on 12/20/24. Standard corporate update, no major news in excerpt.
AI Summary
On December 20, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices in Malvern, PA. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing serves as a notification to the SEC and investors about the company's status and any material events. Investors should review the full filing for details on significant corporate actions.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information about significant financial risks or operational changes.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Malvern, PA (location) — Principal executive offices
- December 20, 2024 (date) — Date of report
FAQ
What is the primary business of Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When was this Form 8-K filed?
This Form 8-K was filed on December 20, 2024.
Where are Galera Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Galera Therapeutics, Inc. are located at 45 Liberty Blvd #230, Malvern, PA 19355.
What is the state of incorporation for Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Galera Therapeutics, Inc.?
The SEC file number for Galera Therapeutics, Inc. is 001-39114.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 12.6 · Accepted 2024-12-20 16:42:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX OTC Pink M
Filing Documents
- d918483d8k.htm (8-K) — 26KB
- 0001193125-24-283187.txt ( ) — 146KB
- grtx-20241220.xsd (EX-101.SCH) — 3KB
- grtx-20241220_lab.xml (EX-101.LAB) — 18KB
- grtx-20241220_pre.xml (EX-101.PRE) — 11KB
- d918483d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: December 20, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer